Navigation Links
Watson Launches Omeprazole Delayed-Release Capsules, 40MG
Date:7/25/2008

- 180-Days of Marketing Exclusivity Begins -

CORONA, Calif., July 25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that its subsidiary has commenced commercial shipment of its Omeprazole Delayed-Release Capsules USP product in the 40mg strength from its Davie, Florida manufacturing facility. In conjunction with the launch, Watson has 180 days of marketing exclusivity for being the first to file an ANDA containing a paragraph IV certification for the 40mg strength.

Omeprazole is the generic equivalent to AstraZeneca's Prilosec(R) Delayed-Release Capsules USP and is indicated for the short-term treatment of active duodenal ulcer. For the 12-months ending March 2008, Prilosec(R) Delayed-Release Capsules and its generic equivalents had total U.S. sales of approximately $200 million, according to IMS Health.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2007.

Prilosec(R) is a registered trademark of the AstraZeneca group of companies.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Much attention has been paid to the problem ... on opioid painkillers has fallen short. From 1999 until 2010, fatal overdoses from prescription ... fatal overdoses in male populations.(1) , The proportion of women using illicit drugs is ...
(Date:2/27/2017)... ... 27, 2017 , ... This webinar , sponsored by ... tool to characterize particle size distributions in the field of geoscience and soil ... scientific findings. It describes methods of optimized and standardized sample collection, preparation and ...
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast Health Centre ... Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of ... showcases the Centre's commitment to innovation in drug rehab and alcohol treatment strategies ...
(Date:2/26/2017)... MICHIGAN (PRWEB) , ... February 25, 2017 , ... The ... Kim Jong-un, heightened awareness and concern over nerve agents and the deadly use of ... the human nervous system and how even small doses can be lethal. , Jay ...
(Date:2/26/2017)... New York (PRWEB) , ... February 26, 2017 ... ... baby products for wholesale distribution in North America, today announced it would be ... sites. The company, which prides itself on crafting quality and unique baby clothing/feeding ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Israel , Feb. 27, 2017 ... of adult stem cell technologies for neurodegenerative diseases, announced ... M.D., Ph.D., FACP, and Arturo O. Araya , ... "Dr. Almenoff and Mr. Araya are talented and ... time for our company," said Chaim Lebovits , ...
(Date:2/24/2017)... NEW YORK , February 24, 2017 Following ... Israel , s ... $ 250 M w ound care ... file s BST for inclusion in ... national healthcare reimbursement system   E-QURE Corp. ...
(Date:2/24/2017)... -- Research and Markets has announced the addition of the ... their offering. ... research Hemophilia Drugs Price Analysis and Strategies - 2016, provides drug pricing ... the following questions: What are the key ... in the Global Hemophilia market? What are the unit ...
Breaking Medicine Technology: